A Multicenter, Randomized, Investigator- and Subject-Blind, Placebo-Controlled, Treatment Sequence Study Evaluating the Safety, Tolerability, and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Aug 2018
At a glance
- Drugs Rozanolixizumab (Primary)
- Indications Myasthenia gravis
- Focus Therapeutic Use
- Sponsors UCB Biopharma
- 11 Aug 2018 This trial was completed in Belgium (end date: 2018-08-06), according to European Clinical Trials Database.
- 07 Aug 2018 This trial was completed in Denmark, according to European Clinical Trials Database.
- 14 Jun 2018 This trial has been completed in Germany end date (2018-05-30).